KIT exon 9 GIST has shorter PFS on imatinib 400 mg vs exon 11. Imatinib 800 mg/day (split...
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | BMA-KIT-EXON9-GIST |
|---|---|
| Art | Therapeutische Relevanz |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Erkrankungen | DIS-GIST |
| Quellen | SRC-CIVIC SRC-IRIS-OBRIEN-2003 SRC-NCCN-MELANOMA-2025 |
Fakten zur Handlungsfähigkeit
| Biomarker | BIO-KIT |
|---|---|
| Variante | exon 9 Einsetzen (extrazelluläre Domäne — ~10% GIST, überwiegend Dünndarm) |
| Erkrankung | DIS-GIST |
| ESCAT-Stufe | IB |
| Empfohlene Kombinationen | imatinib 800 mg/day split BID (1L advanced/metastatic exon 9) |
| Kontraindizierte Monotherapie | imatinib 400 mg/day as 1L for exon 9 (inferior PFS — escalate to 800 mg) |
| Zusammenfassung der Beweise | KIT exon 9 GIST has shorter PFS on imatinib 400 mg vs exon 11. Imatinib 800 mg/day (split 400 mg BID) improves PFS and OS vs 400 mg in this genotype (EORTC-62005 / MetaGIST meta-analysis, Gastrointest Stromal Tumor Meta-Analysis 2010). High dose is standard 1L for exon 9. |
Anmerkungen
ESCAT IB. OncoKB Level 1. Source-gap as DIS-GIST. Adjuvant strategy in high-risk resected exon-9 GIST less established — extended- duration imatinib often considered. Exon 9 GIST predominantly small-bowel primary; extra-gastric origin should prompt KIT exon 9 testing if not already done.
Verwendet von
Keine Rückverweise im YAML-Korpus gefunden.